Health
Breakthrough Endometriosis Treatment Approved in Australia
A groundbreaking endometriosis treatment has been given the green light in Australia, marking a significant milestone in the management of this chronic condition. The Therapeutic Goods Administration has approved Ryeqo, a revolutionary once-daily tablet developed by Gedeon Richter Australia to alleviate the excruciating pain endured by endometriosis sufferers.
Endometriosis, a condition affecting at least one in nine girls and women globally, involves the abnormal growth of uterine tissue outside the uterus, leading to severe inflammation and debilitating symptoms. Despite the prevalence of the condition, treatment options have been limited for over a decade.
Ryeqo’s approval by the TGA signals a new era in endometriosis care, offering patients a tangible solution to manage their symptoms and prevent tissue overgrowth. However, the tablet’s exclusion from the Pharmaceutical Benefits Scheme means patients will bear the full cost of approximately $135 per month until a reimbursement decision is reached by the PBAC in March.
Leading experts in women’s health, including Prof Susan Davis from Monash University, have hailed the approval of Ryeqo as a significant advancement in endometriosis treatment. With its unique mechanism targeting estrogen-progestogen imbalances, the tablet presents a promising option for those struggling with the condition.
Gynaecologist and endometriosis specialist Prof Gino Pecoraro of The Wesley Hospital in Brisbane emphasized the significance of this new treatment, underscoring the relief it can bring to countless women living with the debilitating effects of endometriosis. CEO of Endometriosis Australia, Maree Davenport, echoed these sentiments, highlighting the importance of a non-contraceptive alternative for pain management.
As Ryeqo becomes available for endometriosis patients in Australia, it represents a significant milestone in the ongoing efforts to enhance treatment options and address the varied needs of individuals battling this complex condition.
